# Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct01646320` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01646320](<https://clinicaltrials.gov/study/NCT01646320>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01646320

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 320 participants.

## Technical summary

Registry record NCT01646320. Randomized; triple masking; primary purpose treatment. Start 2012-09 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2016-04-11.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 320 participants (enrolled count; ClinicalTrials.gov record NCT01646320, source copy `cardio:ctgov-nct01646320-2016-06-22`, retrieved 2026-10-26)
- Start date: 2012-09 (registry gives no type) (ClinicalTrials.gov record NCT01646320, source copy `cardio:ctgov-nct01646320-2016-06-22`, retrieved 2026-10-26)
- Primary completion: 2014-08 (actual) (ClinicalTrials.gov record NCT01646320, source copy `cardio:ctgov-nct01646320-2016-06-22`, retrieved 2026-10-26)
- Completion: 2015-02 (actual) (ClinicalTrials.gov record NCT01646320, source copy `cardio:ctgov-nct01646320-2016-06-22`, retrieved 2026-10-26)
- Results first posted: 2016-04-11 (ClinicalTrials.gov record NCT01646320, source copy `cardio:ctgov-nct01646320-2016-06-22`, retrieved 2026-10-26)
- Countries: United States; Czechia; Mexico; Poland; Puerto Rico; Romania; Russia; United Kingdom (ClinicalTrials.gov record NCT01646320, source copy `cardio:ctgov-nct01646320-2016-06-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01646320-2016-06-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): Placebo matching with Dapagliflozin
- Intervention (Drug): Saxagliptin
- Intervention (Drug): Metformin immediate release (IR)
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes (`cardio:pubmed-26246458`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: b162d986258e64f313f8e07d621e92bb8a850a61e23684c756e5d5a3d6350bd3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
